Shots and injection sites
How to Inject Zepbound and Mounjaro Pens
How to inject Zepbound or Mounjaro: the pen steps, what each click means, how long to hold, sites, bubbles, storage and the KwikPen difference.
Guides
Zepbound Injection Site Reaction Explained
A red or itchy Zepbound injection site is a documented reaction: the label groups erythema and pruritus among its injection site reactions, which occurred in 6% to 8% of people on tirzepatide against 2% on placebo in pooled weight-management trials. Mounjaro's label reports 3.2% against 0.4% in type 2 diabetes trials. Lilly Germany grades 91% of Mounjaro EU injection site reactions as mild. The labels name anaphylaxis and angioedema as the serious reactions to watch for. Neither label gives a duration for a local reaction.
In short
- Zepbound's US label lists injection site reactions in 6% to 8% of people on tirzepatide and 2% on placebo in pooled weight-management trials.
- Mounjaro's US label reports 3.2% on tirzepatide against 0.4% on placebo in type 2 diabetes trials.
- Both labels name anaphylaxis and angioedema as serious hypersensitivity reactions.
How common is a Zepbound injection site reaction, by the label?
The Zepbound prescribing information lists injection site reactions in 6% of people at 5 mg and 8% at 10 mg and 15 mg, against 2% on placebo. The Mounjaro prescribing information gives a single pooled figure for type 2 diabetes trials.
| Medicine and trial population | Tirzepatide | Placebo |
|---|---|---|
| Zepbound 5 mg, weight management (N=630 vs 958) | 6% | 2% |
| Zepbound 10 mg, weight management (N=948 vs 958) | 8% | 2% |
| Zepbound 15 mg, weight management (N=941 vs 958) | 8% | 2% |
| Mounjaro US label, type 2 diabetes, all doses pooled | 3.2% | 0.4% |
| Mounjaro EU weight-management trials, via Lilly Germany | 8% to 8.6% | 1.8% to 2.6% |
Rates come from pooled trials in each label. The populations differ, so the weight-management and diabetes rows should not be read as one scale.
The Zepbound category groups bruising, erythema, pruritus, pain, rash and a general 'reaction' term. Separately, the label lists hypersensitivity reactions at 3% on placebo and 5% at each dose. The Mounjaro EU figures, as reported by Lilly Germany's medical information, grade 91% of reactions as mild and 9% as moderate.
Why does the skin react at the injection site?
The labels do not explain why the skin reacts. They count reactions and group the local signs, such as redness, itching and pain, without naming a cause.
One finding is on record. The Mounjaro label's pool of seven trials found injection site reactions in 4.6% (119 of 2,570) of people with anti-tirzepatide antibodies and 0.7% (18 of 2,455) of those without. That shows an association. It does not show that antibodies cause the reaction.
Does rotating injection sites prevent reactions? The labels' tables do not test it, so no trial figure answers that. The pen's instructions for use are the place to check how to choose a site, and a prescriber or pharmacist can clarify it.
How long does an injection site reaction last?
Neither label gives a start time, peak or duration for injection site reactions. The tables report how often reactions occurred over whole trials, not when.
The Zepbound figures do show a pattern by dose: 6% at 5 mg and 8% at 10 mg and 15 mg. That describes how many people had a reaction, not how long one lasted. Which dose you take is your prescriber's decision.
A reaction that worsens or comes with other symptoms is worth raising with your prescriber. To see how recent your last shot was, the GLP-1 half-life calculator estimates how much tirzepatide is left from your dose and timing. For a label-based view of how a dose declines week by week, see a week-by-week decay table for Ozempic beside Mounjaro.
What helps a sore, itchy or red injection site?
The Zepbound and Mounjaro labels list no home treatment for a mild injection site reaction. What they do give is a clear line between local reactions and serious ones, and these steps follow from it.
- Look at the spot against the label's warning signs. The labels name anaphylaxis and angioedema as serious reactions, covered below.
- Follow the pen's instructions for use. The leaflet supplied with the pen is the source for preparing and choosing a site.
- Note where and when it happened. A written record lets you or your prescriber see whether reactions cluster around one area.
- Ask a pharmacist about itch relief. The labels do not recommend a product, so this is a question for a professional.
- Tell your prescriber if it does not ease. Any decision about your dose or schedule is theirs to make, not yours to make alone.
How is an injection site reaction different from a serious allergic reaction?
An injection site reaction is a skin reaction at the spot of the shot, and the Zepbound label counts it apart from hypersensitivity. That label lists hypersensitivity in 5% of people on tirzepatide and 3% on placebo, and says most were skin reactions such as rash and itching.
Both labels also report serious hypersensitivity reactions, for example anaphylaxis and angioedema. The Mounjaro label adds that urticaria and eczema have been reported, sometimes severely.
Mention either a local reaction or a rash or itch to your prescriber, and use the next section for what needs urgent care.
When does an injection site reaction need a doctor or emergency care?
The Zepbound label's hypersensitivity warning (section 5.6) says serious hypersensitivity reactions, for example anaphylaxis and angioedema, have been reported. It advises patients to seek medical attention promptly and to discontinue use if a reaction is suspected.
The Mounjaro label (section 5.4) also reports serious hypersensitivity reactions, for example anaphylaxis and angioedema. It says to discontinue and treat promptly per standard of care if they occur.
The signs the labels name:
- Anaphylaxis, a severe whole-body allergic reaction.
- Angioedema, which is swelling beneath the skin.
- Urticaria or eczema, which the Mounjaro label says have been reported, sometimes severely.
Anyone with signs of a serious reaction should seek emergency care. Whether to continue the medicine is for the prescriber. For a mild local reaction that is not easing or is getting worse, contact your prescriber or pharmacist.
Where can you log your injection sites?
Dose & Lose is a tracking app, and its dose log records each shot with the medication, dose, date and time, injection site, a pain level from 0 to 10 and notes. It can also show where past shots went, so a pattern can be spotted and shown to a prescriber.
You can rate side effects from 0 to 10 day by day and see them next to your doses. With rotation turned on, the app suggests the next site on the other side, and you choose. It does not diagnose or classify a reaction. See the Dose & Lose app. If you are on an early dose, see how Mounjaro's effect builds over about 4 weeks per dose.
Frequently asked questions
Can you keep injecting in the same spot if it is not reacting?
The labels do not say, because their reaction tables do not compare sites. Neither label's figures test whether staying in one spot changes the rate. How to choose a site is set out in the instructions for use that come with the pen, so ask your prescriber or pharmacist if unsure.
Is it normal to get a reaction weeks after starting, not just the first dose?
The labels do not say when reactions start, because their tables pool whole trials. Zepbound's label reports 6% to 8% on tirzepatide in pooled weight-management trials, against 2% on placebo. A new or changing reaction on any week is worth mentioning to your prescriber.
Does a reaction mean the dose is not absorbing properly?
The labels do not link injection site reactions to absorption. Their reaction tables report how often reactions occurred, not how much medicine reached the blood. If you are worried that a shot leaked or went wrong, describe what happened to your prescriber or pharmacist rather than judging from the skin.
Is a small lump under the skin after a shot the same as a reaction?
The labels do not name lumps, so the answer is unclear. Zepbound's table groups bruising, erythema, pruritus, pain, rash and a general 'reaction' term in one category. A lump that grows, hurts or does not ease is worth showing your prescriber.
Sources
- Zepbound prescribing information, DailyMed: Table 1 reaction rates by dose (section 6.1) and the hypersensitivity warning (section 5.6).
- Mounjaro prescribing information, DailyMed: injection site reaction rates and antibody split (section 6.1) and the hypersensitivity warning (section 5.4).
- Lilly Germany medical information on Mounjaro reactions: EU figures by indication and severity.
Published by Petros IT Solutions SRL, written by the Dose & Lose Editorial Team. Corrections: office@doseandlose.com.